T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VISN
2226
Vistance Networks Inc
VISN
$2.67B
| $682K | ﹤0.01% |
61,734
-22,971
| -27% | -$252K |
|
2227
Pulmonx
LUNG
$98.4M
| $679K | ﹤0.01% |
21,183
-390,204
| -95% | -$14.3M |
|
|
VIVO
2228
DELISTED
Meridian Bioscience Inc
VIVO
| $679K | ﹤0.01% |
33,308
-2,600
| -7% | -$49.9K |
|
2229
MYR Group
MYRG
$5.18B
| $678K | ﹤0.01% |
6,137
-256
| -4% | -$27.8K |
|
2230
First Financial Corp
THFF
$970M
| $677K | ﹤0.01% |
14,950
+1,356
| +10% | +$59.7K |
|
2231
Unitil
UTL
$984M
| $677K | ﹤0.01% |
14,722
-389
| -3% | -$16.9K |
|
2232
AppFolio
APPF
$6.97B
| $676K | ﹤0.01% |
5,587
-2,384
| -30% | -$302K |
|
2233
First Busey Corp
BUSE
$2.58B
| $676K | ﹤0.01% |
24,942
-4,577
| -16% | -$121K |
|
2234
National Presto Industries
NPK
$998M
| $676K | ﹤0.01% |
8,244
+3,200
| +63% | +$268K |
|
|
EGRX
2235
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $676K | ﹤0.01% |
13,267
-208
| -2% | -$10.8K |
|
2236
Icon
ICLR
$12.9B
| $675K | ﹤0.01% |
2,181
| – | – |
|
|
RAD
2237
DELISTED
Rite Aid Corporation
RAD
| $675K | ﹤0.01% |
45,977
+6,008
| +15% | +$81K |
|
2238
Riot Platforms
RIOT
$7.21B
| $672K | ﹤0.01% |
30,081
-2,884
| -9% | -$85.9K |
|
2239
Transocean
RIG
$6.39B
| $666K | ﹤0.01% |
241,320
| – | – |
|
|
RBCP
2240
DELISTED
RBC Bearings Incorporated 5.00% Series A Mandatory Convertible Preferred Stock
RBCP
| $665K | ﹤0.01% |
6,381
-619
| -9% | -$69K |
|
|
RCM
2241
DELISTED
R1 RCM Inc. Common Stock
RCM
| $664K | ﹤0.01% |
26,051
-9,907
| -28% | -$237K |
|
|
SRG
2242
Seritage Growth Properties
SRG
$131M
| $663K | ﹤0.01% |
49,967
-7,103
| -12% | -$104K |
|
2243
FuelCell Energy
FCEL
$1.63B
| $662K | ﹤0.01% |
4,246
-2,664
| -39% | -$628K |
|
2244
Blue Owl Capital
OWL
$19.7B
| $662K | ﹤0.01% |
44,400
+20,000
| +82% | +$316K |
|
2245
Pembina Pipeline
PBA
$28.4B
| $662K | ﹤0.01% |
21,808
-1
| -0% | -$32 |
|
2246
Green Plains
GPRE
$1.06B
| $661K | ﹤0.01% |
19,026
+8,240
| +76% | +$306K |
|
|
OPI
2247
DELISTED
Office Properties Income Trust
OPI
| $661K | ﹤0.01% |
26,617
-818
| -3% | -$21K |
|
2248
Scansource
SCSC
$1.06B
| $659K | ﹤0.01% |
18,793
-449
| -2% | -$15.8K |
|
2249
Olema Pharmaceuticals
OLMA
$913M
| $657K | ﹤0.01% |
+70,172
| New | +$1.45M |
|
2250
Community Health Systems
CYH
$410M
| $655K | ﹤0.01% |
49,229
-2,359
| -5% | -$29.6K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.